{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:45:22Z","timestamp":1778539522917,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.euo.2018.08.032","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T08:48:00Z","timestamp":1538815680000},"page":"576-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"2","author":[{"given":"Marco","family":"Racioppi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0564-7415","authenticated-orcid":false,"given":"Luca","family":"Di Gianfrancesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Ragonese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4640-8354","authenticated-orcid":false,"given":"Emilio","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PierFrancesco","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2018.08.032_bib0210","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0215","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0220","series-title":"Campbell's urology","first-page":"2327","article-title":"Urothelial tumors of the urinary tract","author":"Messing","year":"1998"},{"key":"10.1016\/j.euo.2018.08.032_bib0225","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1505::AID-CNCR19>3.0.CO;2-3","article-title":"The National Cancer Data Base report on bladder carcinoma","volume":"78","author":"Fleshner","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2018.08.032_bib0230","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)68208-0","article-title":"Bladder Cancer Clinical Guidelines Panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS)","volume":"162","author":"Smith","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0235","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)66443-9","article-title":"Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy","volume":"165","author":"Holmang","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0240","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eururo.2006.08.038","article-title":"Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta\u2013T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder","volume":"51","author":"Maffezzini","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1464-410X.1994.tb16585.x","article-title":"Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin","volume":"74","author":"Popert","year":"1994","journal-title":"Br J Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0250","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.juro.2006.06.007","article-title":"Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response","volume":"176","author":"van der Heijden","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0255","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1464-410X.1996.09002.x","article-title":"Phase II trials in Ta, T1 bladder cancer. The marker tumour concept","volume":"77","author":"van der Meijden","year":"1996","journal-title":"Br J Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0260","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000472938","article-title":"Intravesical chemoresection with 40-epi-doxorubicin in patients with superficial bladder tumors","volume":"14","author":"Calais da Silva","year":"1988","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0265","first-page":"5144","article-title":"Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients","volume":"51","author":"Dalton","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2018.08.032_bib0270","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/jnci\/53.5.1341","article-title":"Characterization of a cell line from human transitional cell cancer of the urinary tract","volume":"53","author":"Elliott","year":"1974","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2018.08.032_bib0275","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1054\/bjoc.2000.1641","article-title":"Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion","volume":"84","author":"Fujiyama","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2018.08.032_bib0280","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1208\/s12248-010-9219-8","article-title":"Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs","volume":"12","author":"Hu","year":"2010","journal-title":"AAPS J"},{"key":"10.1016\/j.euo.2018.08.032_bib0285","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0022-5347(01)66827-7","article-title":"A model of bladder tumor xenografts in the nude rat","volume":"154","author":"Oshinsky","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0290","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"10.1016\/j.euo.2018.08.032_bib0295","first-page":"31","article-title":"Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history","volume":"10","author":"Pasin","year":"2008","journal-title":"Rev Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0300","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-5347(01)61606-9","article-title":"Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and longterm followup","volume":"161","author":"Solsona","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0305","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","article-title":"Should all patients with non\u2013muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study","volume":"55","author":"Gudj\u00f3nsson","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0310","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"Di Stasi","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2018.08.032_bib0315","series-title":"The commonly advocated doses for mitomycin C are 2\u201340mg. In European Association of Urology guideline on bladder cancer","first-page":"9","author":"Oosterlinck","year":"2001"},{"issue":"Suppl 4","key":"10.1016\/j.euo.2018.08.032_bib0320","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1464-410X.2012.11619.x","article-title":"Intravesical therapies for bladder cancer\u2014indications and limitations","volume":"110","author":"Logan","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2018.08.032_bib0325","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2018.08.032_bib0330","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000315492","article-title":"Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach","volume":"85","author":"Racioppi","year":"2010","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2018.08.032_bib0335","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.eururo.2012.05.032","article-title":"Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomized phase 2 study","volume":"62","author":"Colombo","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0340","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0345","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.juro.2007.05.148","article-title":"Management of low grade papillary bladder tumors","volume":"178","author":"Herr","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0350","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1046\/j.1464-410X.2002.02734.x","article-title":"A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder","volume":"89","author":"Malmstr\u00f6m","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2018.08.032_bib0355","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/CEOR.S135065","article-title":"Cost of illness of urothelial bladder cancer in Italy","volume":"9","author":"Gerace","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.euo.2018.08.032_bib0360","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","article-title":"Expectant management of small, recurrent, noninvasive papillary bladder tumors","volume":"170","author":"Soloway","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0365","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.juro.2007.08.171","article-title":"Conservative management of low risk superficial bladder tumors","volume":"179","author":"Pruthi","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0370","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2018.08.032_bib0375","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","article-title":"Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review","volume":"109","author":"Shelley","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2018.08.032_bib0380","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC)","volume":"46","author":"Gontero","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2004.08.027","article-title":"Gemcitabine in intravesical treatment of Ta\u2013T1 transitional cell carcinoma of bladder: phase I\u2013II study on marker lesions","volume":"65","author":"Serretta","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.euo.2018.08.032_bib0390","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1569-9056(04)90480-0","article-title":"Intravesical administration of gemcitabine for the chemoresection of superficial bladder cancer: a marker lesion study","volume":"3","author":"De Berardinis","year":"2004","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.euo.2018.08.032_bib0395","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1569-9056(05)80881-4","article-title":"Phase 2 study 2000mg of intravesical gemcitabine in marker lesions","volume":"4","author":"Calais da Silva","year":"2005","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.euo.2018.08.032_bib0400","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1569-9056(07)60147-X","article-title":"Phase II marker lesion study of 6-week intravesical gemcitabine instillation in patients with low risk non muscle invasive bladder tumours","volume":"6","author":"Brausi","year":"2007","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.euo.2018.08.032_bib0405","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.eururo.2009.06.010","article-title":"Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicenter study","volume":"56","author":"B\u00f6hle","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2018.08.032_bib0410","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931118301512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931118301512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:45:10Z","timestamp":1762875910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931118301512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2588931118301512"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2018.08.032","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2018.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}